NCT03242564 is a NA clinical trial of Vevazz LED in Obesity, sponsored by Vevazz, LLC.

Who is sponsoring NCT03242564?

NCT03242564 is sponsored by Vevazz, LLC.

What drugs are being tested in NCT03242564?

Interventions in NCT03242564: Vevazz LED.

Is NCT03242564 still recruiting?

NCT03242564 is currently completed. Last updated 8 August 2017.

Last reviewed 2017-08-08 · How we verify

NCT03242564

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Red Light LED Therapy on Body Contouring

Completed NA Last updated 8 August 2017

What this trial tests

NA trial testing Vevazz LED in Obesity in 66 participants. Completed in 21 July 2017.

Timeline

10 July 2017

Primary endpoint
21 July 2017

21 July 2017

Quick facts

Lead sponsor	Vevazz, LLC
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	66
Start date	10 July 2017
Primary completion	21 July 2017
Estimated completion	21 July 2017
Sites	1 location across United States

Drugs / interventions tested

Vevazz LED

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

Vevazz, LLC

Who can join

Adults 18 to 77, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether red light therapy using LED 650nm red light for body contouring of the waist, hips and thighs is as effective as red light therapy using Laser 635nm red light.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03242564 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vevazz, LLC
Last refreshed: 8 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03242564.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing